Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

NCT00082784 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

93

Enrollment

NIH

Sponsor class

Conditions

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Nodal Marginal Zone Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Refractory Plasma Cell Myeloma
Splenic Marginal Zone Lymphoma
Waldenstrom Macroglobulinemia

Interventions

DRUG: Bortezomib
DRUG: Alvocidib Hydrochloride
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)